Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Recent Videos
Marion Munk, MD, PhD, presenting slides
Related Content
Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101

Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101

David Hutton
December 6th 2024
Article
EyePoint doses first patient in second global Phase 3 LUCIA clinical trial of Duravyu for the treatment of wet AMD

EyePoint doses first patient in second global Phase 3 LUCIA clinical trial of Duravyu for the treatment of wet AMD

David Hutton
December 5th 2024
Article
More than 300 patients randomized in the SOL-1 Phase 3 trial for OTX-TKI

More than 300 patients randomized in the SOL-1 Phase 3 trial for OTX-TKI

Sydney M Crago
December 3rd 2024
Article
Oral presentation discussing sozinibercept set for the annual FLORetina Congress

Oral presentation discussing sozinibercept set for the annual FLORetina Congress

Sydney M Crago
December 2nd 2024
Article
AI models offer hope for personalized AMD treatment plans

AI models offer hope for personalized AMD treatment plans

David Hutton
November 27th 2024
Article
What you missed at AAO 2024: ABBV-RGX-314 for wet AMD

What you missed at AAO 2024: ABBV-RGX-314 for wet AMD

Sydney M Crago
November 27th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.